pneumococcal polysaccharide serotype 19A CRM197 conjugate vaccine adsorbed on aluminium phosphate

The pneumococcal polysaccharide serotype 19A CRM197 conjugate vaccine adsorbed on aluminium phosphate is a monovalent vaccine candidate developed by the Rijksinstituut voor Volksgezondheid en Milieu (RIVM) and Intravacc. It is specifically designed to provide immunity against Streptococcus pneumoniae serotype 19A, a major cause of invasive pneumococcal disease that emerged as a significant pathogen following the introduction of early multivalent vaccines that did not cover this serotype. The vaccine utilizes a conjugation technology where the 19A capsular polysaccharide is covalently bound to CRM197, a non-toxic recombinant mutant of the diphtheria toxin. This conjugation converts the polysaccharide from a T-cell independent to a T-cell dependent antigen, thereby inducing a more robust immune response and immunological memory, particularly in infants. The formulation is adsorbed onto aluminium phosphate, which serves as an adjuvant to further enhance the humoral immune response.

Other names

Monovalent pneumococcal serotype 19A conjugate vaccine19A-CRM197